Panacea Biotec (BOM:531349) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:531349 Panacea Biotec Ltd BOM:531349
54 GF Score
Price ₹538.20
GF Value ₹359.92
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Panacea Biotec FFO?

FFO (Funds from operations) only applies to REITs.

BOM:531349
54GF Score
Panacea Biotec Ltd BOM:531349
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Panacea Biotec (BOM:531349) Overvalued in 2026?

Based on GuruFocus' analysis, Panacea Biotec stock appears to be overvalued. The current stock price of ₹538.20 is trading 49.5% above its estimated GF Value™ of ₹359.92. GuruFocus considers Panacea Biotec to be Significantly Overvalued.

Key valuation signals for BOM:531349:

  • FFO:
  • GF Value™: ₹359.92 vs. price of ₹538.20 (49.5% above fair value)
  • GF Score™: 54/100 with 3 warning signs

No single metric tells the full story. See the BOM:531349 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Panacea Biotec Business Description

Other Exchanges PANACEABIO:India
Address Mathura Road, B-1 Extension/G-3, Mohan Co-operative Industrial Estate, New Delhi, IND, 110044
Panacea Biotec Ltd is a Biotechnology company. It is engaged in the business of research, development, manufacturing, and marketing of branded pharmaceutical formulations, vaccines, and biopharmaceuticals. The company's operating segments include Vaccines, and Formulations. It generates maximum revenue from the Vaccines segment. The company product portfolio includes prescription products in niche therapeutic areas such as diabetes and cardiovascular management, oncology, nephrology and transplant management, osteoporosis management, gastro-intestinal care, pain management products, and pediatric immunization. The group has a business presence in India and Outside India.
54GF Score

Get the complete analysis for BOM:531349

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹538.20
Price
₹359.92
GF Value